A Study to Determine the Effect of Famotidine on the Drug Levels of BMS-986256 in Healthy Participants

• Status: Not yet recruiting
• Trial end date: 2021-09-09
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to investigate the effect of gastric pH changes induced by famotidine on the drug levels of BMS-986256.

• Phase: Phase 1
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Bristol-Myers Squibb
• Treatments: Famotidine

Criteria

For more information regarding Bristol-Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com

Inclusion Criteria:

• Healthy participants, defined as having no clinically significant deviations from normal in medical history

• Weight ≥ 50 kg and body mass index between 18.0 kg/m2 and 32.0 kg/m2, inclusive, at screening

• Normal renal function at screening

Exclusion Criteria:

• Any significant acute or chronic medical illness

• Current or recent gastrointestinal (GI) disease that could impact upon the absorption of study treatment

• Any major surgery within 4 weeks of study treatment administration

• Significant history of GI abnormalities

Other protocol-defined inclusion/exclusion criteria apply